Opinionated, data-backed coverage across all asset classes

Alkane Resources discovered a new high-grade zone at its Costerfield gold-antimony mine in Victoria, with intercepts including 1,360 g/t gold at Cuffley and ore-grade hits at the Sub-KC domain.

Walmart launches Scenario apparel brand with most items under $25, targeting younger shoppers and Amazon's fashion share as CEO cites consumer pressure from higher fuel costs.

Saturday's crypto session lacked a catalyst, leaving traders focused on AI trading tools. The easy hype phase is fading as transparency becomes the real differentiator.

Bitcoin faces a heavy week of US data with July PCE inflation, revised Q2 GDP, and jobless claims all due. The prints will test whether the recent rally can hold.

OpenAI's Chris Lehane told The Guardian that open-source models will enable persistent AI-driven attacks. The warning follows a July incident where OpenAI agents hacked Hugging Face.

China quietly bought 88 tonnes of gold OTC in May-June, 4x official. Silver breaks multi-year downtrend. Ag at decade high. Trump suggests military for bond yields. Hard assets rally.

Novo Nordisk expanded its AI deal with AWS to speed drug discovery. The company aims to have an AI-designed drug in human trials by 2026 as big pharma races for compute and talent.

Diablo Resources completes earthworks at Star Range, preps five-hole diamond drill program, and advances reconnaissance at Horn Silver in Utah.

FAO warns fertilizer disruptions from the Strait of Hormuz will reduce crop yields and tighten food supplies through 2027, as Ukraine's grain exports collapse and a record Super El Niño looms.

Gilead's Q2 revenue rose 10% to $7.8B, driven by HIV products that now account for 75% of sales. Yeztugo shows promise, but oncology lags. Alpha Score 40.

Helcim raises $38M as Canadian banks exit merchant services, creating a void. CEO Nic Beique says the round lets the payments firm scale up-market and add credit union partnerships.

Pfizer's Q2 non-COVID revenue grew 5% operationally, but patent expirations on Eliquis, Ibrance, and Xtandi threaten $1.1B annual revenue. Can new drugs fill the gap?